TURBT术后吡柔比星膀胱灌注预防肿瘤复发的疗效分析  

Intravesical instillation of pirarubicin(THP) in prophylactic treatment after transurethral resection of bladder cancer

作　　者：王建伯[1] 宋希双[1] 车翔宇[1] 吴东军[1] 张仁科[1] 殷积斌[1] 

机构地区：[1]大连医科大学附属第一医院泌尿外科,辽宁大连116011

出　　处：《大连医科大学学报》2008年第2期138-140,共3页Journal of Dalian Medical University

摘　　要：[目的]评价吡柔比星（THP）膀胱灌注预防膀胱肿瘤TURBT术后复发的疗效和安全性。[方法]1999年11月-2003年10月，膀胱肿瘤TURBT术后患者63例，术后接受THP30mg膀胱灌注治疗，随访12-53个月。[结果]膀胱癌TURBT术后THP膀胱灌注，术后1年未复发率89．8％，术后2年未复发率83．1％，术后3年未复发率76．3％；膀胱灌注THP副反应发生率为28．57％。[结论]应用THP30mg／50mL（600μg／mL），TURBT术后尽早膀胱灌注，膀胱内保留30min，采用为期1年的短期疗程，对于预防膀胱肿瘤TURBT术后复发有较好的疗效。[ Objective ] To evaluate the effectiveness and safety of intravesical instillation of THP after transurethral resection of bladder cancer （TURBT）. [ Methods] From Nov. 1999 to Oct. 2003, a total of 63 patients were treated with intravesical instillation of THP after TURBT, the patients were followed up by cystscopy for 12-53 months. [Results] The non-recurrence rates at 1, 2 and 3 years were 89.8% , 83.1% and 76.3% , respectively. The side effect rate was 28.57%. [ Conclusions ] Our findings demonstrated that short-term （1 year）, 30 minutes instillation intensive intravesical instillation of THP 30 mg/50 mL （600 μg/mL） after TURBT was a safe and effective therapy.

关 键 词：膀胱肿瘤 吡柔比星 TURBT 膀胱灌注 

分 类 号：R737.14[医药卫生—肿瘤]